AbCellera Biologics (ABCL) Operating Margin (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Operating Margin came in at 691.75% in Q1 2026, up 78783.0% YoY from N/an in Q1 2025, and down 985.55% on a QoQ basis from 63.72% in Q4 2025.
AbCellera Biologics (ABCL) Operating Margin (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of Operating Margin data on file, last reported at 691.75% in Q1 2026.
- Quarterly Operating Margin rose 78783.0% year-over-year to 691.75% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 267.61% (up 112773.0% YoY) and the FY2025 annual result came in at 288.98%, up 80271.0% from the prior year.
- Operating Margin retreated to 691.75% in Q1 2026, from 63.72% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 71.06% in Q1 2022 to a low of 1479.57% in Q1 2025.
- A 5-year average of 633.22% and a median of 551.48% in 2024 frame the typical range for Operating Margin.
- The widest YoY moves for Operating Margin: up 137697 bps in 2025, down 92810 bps in 2025.
- Tracing ABCL's Operating Margin over 5 years: stood at 175.34% in 2022, then tumbled by 310 bps to 719.61% in 2023, then sank by 100 bps to 1440.69% in 2024, then jumped by 96 bps to 63.72% in 2025, then sank by 986 bps to 691.75% in 2026.
- The last three Operating Margin figures came in at 691.75% (Q1 2026), 63.72% (Q4 2025), and 851.79% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | -1,550.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,550.05% |
| Mar 31, 2026 | -691.75% |
| Dec 31, 2025 | -63.72% |
| Sep 30, 2025 | -851.79% |
| Jun 30, 2025 | -290.24% |
| Mar 31, 2025 | -1,479.57% |
| Dec 31, 2024 | -1,440.69% |
| Sep 30, 2024 | -1,439.42% |
| Jun 30, 2024 | -1,276.17% |
| Mar 31, 2024 | -551.48% |
| Dec 31, 2023 | -719.61% |
| Sep 30, 2023 | -831.79% |
| Jun 30, 2023 | -511.03% |
| Mar 31, 2023 | -532.10% |
| Dec 31, 2022 | -175.34% |
| Sep 30, 2022 | 37.22% |
| Jun 30, 2022 | -18.29% |
| Mar 31, 2022 | 71.06% |
| Dec 31, 2021 | 58.53% |
| Sep 30, 2021 | -510.09% |